Author

Dirk Demuth 1

1 Takeda Development Centre Europe Ltd, Global Outcomes Research, London, United Kingdom

Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler, Andres Yarur, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Sumit Saha, Christina Kifnidi, Dirk Demuth, Haridarshan Patel, Gerassimos J. Mantzaris

COST PER CLINICAL OUTCOMES WITH VEDOLIZUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN BRAZIL

Tassia Decimoni, Gabriela Muricy, Haridarshan Patel, Dirk Demuth

DEFINING ´EARLY DISEASE´ IN INFLAMMATORY BOWEL DISEASE: THE RESULTS OF A SYSTEMATIC LITERATURE REVIEW

Laurent Peyrin-Biroulet, Vipul Jairath, Donna Wright, Dirk Demuth, Sarah Campbell-Hill, Parambir Singh Dulai

Incidence and indicators of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialized countries: Results from the EXPLORE study

Jesus Kazuo Yamamoto-Furusho, Othman Al Harbi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina V. Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M Rana-Khan, Alessandro Armuzzi

REAL WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Stefan Schreiber, Axel Dignass, Laurent Peyrin-Biroulet, Mahmoud Mosli, Greg Hather, Dirk Demuth, Aimee Blake, Rebecca Curtis, Javaria Mona Khalid, Edward V Loftus Jr

Real-world Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results from the EVOLVE study

Andres Yarur, Gerassimos J. Mantzaris, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Christina Kifnidi, Sumit Saha, Dirk Demuth, Haridarshan Patel, Brian Bressler

SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN ADULT ULCERATIVE COLITIS AND CROHN?S DISEASE PATIENTS

Sandra M Bovens, Angela Solaman, Rebecca Curtis, Sharon O'Byrne, Javaria Mona Khalid, Dirk Demuth

VEDOLIZUMAB OUTCOMES IN REAL-WORLD BIO-NAIVE ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS (EVOLVE) IN CANADA: TREATMENT PATTERNS, CLINICAL EFFECTIVENESS AND SAFETY

Brian Bressler, Marielle Bassel, Dara Stein, Mira Soni, Gabriela Radulescu, Astrid-Jane Greenup, Javaria Mona Khalid, Dirk Demuth

VEDOLIZUMAB OUTCOMES IN REAL-WORLD BIO-NAIVE ULCERATIVE COLITIS AND CROHN’S DISEASE PATIENTS (EVOLVE) IN CANADA: TREATMENT PATTERNS, CLINICAL EFFECTIVENESS AND SAFETY

Dirk Demuth

Item 1 - 9 / 9
1